WeWork, Lord & Taylor, and the Artificial Separation of Work and Leisure

Posted by Ken Sawka on Nov 21, 2017 4:18:48 PM

One of my fondest memories growing up in New York was going into “the city” (that’s what we Long Islanders called Manhattan) at Christmastime and going to see the Lord & Taylor Christmas display in its storefront window at its flagship location on Fifth Avenue.  There would be long lines, and we’d wait 20 minutes or more just to get a glimpse of the window.  It was magical.

Read More

Topics: Sales Force Effectiveness, Brand Insights, Market Analysis, Merger and Acquisition, Product Positioning

Quality Drug Data Not a Guarantee of Future Revenue

Posted by David Staknis on Apr 12, 2017 12:07:23 PM

On March 16, 2017, Amgen released positive cardiovascular outcomes data for its PCSK9 inhibitor, Repatha. Yet, it could be tough going to receive wide coverage of the drug from managed care companies due to concerns over high cost and availability of efficacious, economical alternatives. Positive outcomes data alone will not sway payers if the cost-benefit ratio is too high, especially when established and more cost-effective options are available and acceptable.

Read More

Topics: Product Positioning, Competitive Strategy, pharmaceutical

Medication-Induced Syndromes Offer Growth Opportunity

Posted by Kyle Nicholson on Aug 15, 2016 1:40:17 PM

Opioid-induced constipation, tardive dyskinesia, and other medication-induced syndromes present worthwhile revenue opportunities for pharmaceutical R&D.

In the 1960s, researchers discovered that the loss of motor control from Parkinson’s disease (PD) was tied to a deficiency of dopamine in a part of the brain involved in the coordination of movement.

Evidence soon established that administration of levodopa, a dopamine precursor molecule, dramatically improved PD symptoms. Here’s the catch: relief of symptoms was accompanied by severe nausea and vomiting. Levodopa was not only being converted to dopamine in the brain but also in the bloodstream, activating dopamine receptors in the peripheral nervous system and causing the adverse side effects.

Read More

Topics: Pharma, Life Sciences, Product Positioning, Competitive Strategy

Can Apple TV Outshine Netflix and Traditional TV Broadcasters?

Posted by Ken Sawka on Aug 3, 2016 11:41:11 AM

Apple has long been expected to “revolutionize” how we watch television.  Ever since it launched Apple TV in 2006, speculation has been rife that Apple would become a major force in video production and distribution.

Apple’s refresh of Apple TV last year - improving voice search with Siri and adding a bunch more apps - did little to quell that speculation.

Read More

Topics: Brand Insights, Innovation, Market Analysis, Technology/Telecomm, Product Positioning, Competitive Strategy

New White Paper: Competitive Pricing Intelligence

Posted by Fuld + Company on May 3, 2016 2:36:52 PM

Creating an intelligence gathering and analysis process for your organization’s pricing function is essential for sound competitive strategy. Failure to gather and assess this intelligence can lead to pricing strategies that are out of sync with market expectations.

Our latest white paper outlines legal and ethical considerations that must guide how intelligence is gathered on competitor prices, the advantages of continuous intelligence gathering, and how one client leveraged competitive intelligence to raise prices without losing customers or provoking a competitor response. 

Read More

Topics: Competitive Intelligence, Sales Force Effectiveness, Fuld + Company, Market Analysis, Product Positioning, Competitive Strategy

Launching a New Product with Confidence

Posted by Fuld + Company on Mar 14, 2016 10:00:08 AM

For companies planning a new product launch, market and competitive insights can test assumptions about product launch impact and expectations, measure market potential, and anticipate and model competitor response.

Read More

Topics: Product Roadmap, Fuld + Company, Market Analysis, Product Positioning, Competitive Strategy

Is the Chevrolet Bolt a Tesla-Killer?

Posted by Christopher Dent on Jan 14, 2016 1:34:32 PM

The Chevrolet Bolt

Tesla has been synonymous with electric cars for nearly a decade. Sleek, forward-thinking, high-end: that’s the Tesla we know today. Still, from the inception of the Tesla Roadster, CEO Elon Musk has insisted that Tesla’s strategic end-goal is to one day create a “super affordable electric vehicle with mass market appeal.  

That day has finally come. But it’s not Tesla holding the prize. 

Read More

Topics: Brand Insights, Market Analysis, Product Positioning, Competitive Strategy

Filgotinib: Still Early to Pop the Champagne

Posted by Adi Reske on Dec 24, 2015 12:38:39 PM

Recently, Galapagos NV and Gilead entered a partnership, potentially worth more than $2 billion, to develop Galapagos’s oral JAK1 inhibitor, filgotinib, for inflammatory diseases.

Earlier in December 2015, Galapagos announced positive interim Phase II Crohn’s disease results for filgotinib. Based on the data presented, 48% of moderate to severe CD patient treated with filgotinib achieved clinical remission at 10 weeks compared to 23% placebo (p=0.0067); clinical response (CDAI decrease of 100 points or more) as well improvement in patients’ quality of life were also met in the study. According to the company’s CEO, results from the Phase II trial merit moving the drug into a Phase III Crohn's program “as soon as possible”.

Read More

Topics: Brand Insights, Pharma, Life Sciences, Product Positioning

Fuld + Company and Agromeris Partner to Expand Services for Food and Agriculture Industry

Posted by Fuld + Company on Dec 14, 2015 8:00:00 AM


FOR IMMEDIATE RELEASE

BOSTON, MA, December 14, 2015 -- Fuld + Company, a competitive intelligence, strategy, and consulting firm, announced that it has signed a memorandum of understanding with Agromeris, a food and agriculture consulting firm.

The partnership provides Agromeris with methodological expertise and research capacity, drawn from Fuld + Company's 35+ years of experience. Agromeris brings to the partnership 30 years of deep domain expertise across the entire food production value chain, from field to table.

Read More

Topics: Competitive Intelligence, Consumer Goods, Fuld + Company, Manufacturing/Industrial, Market Analysis, Scenario Analysis, Product Positioning, Competitive Strategy

Holiday Gaming - Microsoft's Big Chance

Posted by Robert Flynn on Oct 13, 2015 9:00:00 AM

If Satya Nadella, CEO of Microsoft, has his way, packages under the Christmas tree and exchanged during Chanukah will be full of boxes containing Xbox consoles and games. To increase gaming revenues, he's made some organizational moves assigning Phil Spencer as head of Xbox and Xbox Live, reporting to Windows chief Terry Myerson. But internal changes will not be sufficient in this huge, highly competitive and fast-paced market, especially given Microsoft's slow growth relative to competitors, a laggard performance largely driven by the impact of mobile gaming.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Manufacturing/Industrial, Market Analysis, New Market Entry, Scenario Analysis, Technology/Telecomm, Industry Convergence, Merger and Acquisition, Product Positioning, Competitive Strategy

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.